Trial of Varenicline With Nicotine Lozenges and a Smartphone Medication Adherence Intervention for Smoking Cessation

Conditions

• Smoking Cessation

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Accepted

Interventions

• Varenicline (VAR) — DRUG
  13 weeks of varenicline
• Nicotine lozenge (NRT) — DRUG
  12 weeks of nicotine lozenges
• Smartphone intervention with adherence components (COMBO-A) — BEHAVIORAL
  Smartphone-based smoking cessation intervention with adherence components
• Smartphone intervention without adherence components (COMBO-B) — BEHAVIORAL
  Smartphone-based smoking cessation intervention without adherence components
• Telephone Counseling — BEHAVIORAL
  Up to 6 telephone counseling sessions with a tobacco treatment specialist

Study Details

No published studies to date have evaluated the combined impact of varenicline and oral nicotine replacement therapy (NRT) on smoking cessation in a randomized trial. Oral NRT, such as nicotine lozenges, can provide acute relief from cravings/withdrawal, and offers individuals the flexibility to deliver nicotine quickly, in contrast with the continuous, passive, and slow-acting delivery of the nicotine patch. Nevertheless, in clinical trials of other combination pharmacotherapies, participants' adherence to of oral NRT has been suboptimal, making it difficult to determine whether there is an added benefit. Given the near-ubiquity of smartphone ownership (85% of U.S. adults), it is plausible that smartphone-based medication adherence interventions could have a positive influence on pharmacotherapy adherence and smoking cessation. This investigative team has demonstrated the feasibility and potential efficacy of using combination varenicline plus oral NRT treatment to promote smoking cessation in a pilot factorial randomized trial. Likewise, pilot findings showed that medication adherence and smoking cessation rates were higher among those who received smartphone-based medication reminders than those who did not. The proposed study will enroll 496 adults who smoke cigarettes daily. The study will employ a 2x2 factorial design in which participants will be randomized to one of four combinations of two treatment factors: 1) pharmacological treatment (varenicline + nicotine lozenges vs. varenicline alone) and 2) smartphone medication adherence intervention (smartphone-based smoking cessation app with vs. without adherence components). The primary study outcomes will be biochemically-confirmed 7-day point prevalence abstinence at 26 weeks after a scheduled quit date, and medication adherence over the 13-week treatment period. Smartphone-based daily diaries will be employed to assess daily smoking and medication adherence. Notably, the proposed study will employ entirely remote assessment and treatment delivery strategies. Exploratory analyses will evaluate the potential interaction between medication type and the smartphone adherence intervention, and compare the influences of pharmacological treatment type and the medication adherence intervention on weekly physical symptoms (e.g., withdrawal, medication side effects). The overarching goal of the proposed research is to improve smoking cessation treatment and decrease cancer risk.

Key Dates

First listed

Aug 1, 2025

Start date

Jul 21, 2026

Status verified

Aug 2026

Primary completion

Jun 1, 2029

Completion

Jun 1, 2029

Study Design

Enrollment

496 participants (estimated)

Allocation

RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

TREATMENT

Arms

• Experimental: Varenicline + Smartphone Intervention with adherence components (VAR + COMBO-A)
  Participants will receive 13 weeks of varenicline (1 titration week + 12 weeks at full twice daily 1 mg dosing) and a smartphone-based smoking cessation intervention with medication adherence components. All participants will receive up to 6 telephone counseling calls.
• Experimental: Varenicline + Lozenges + Smartphone Intervention with adherence components (VAR + NRT + COMBO-A)
  Participants will receive 13 weeks of varenicline (1 titration week + 12 weeks at full twice daily 1 mg dosing), 12 weeks of nicotine lozenges (2 mg or 4 mg), and a smartphone-based smoking cessation intervention with medication adherence components. All participants will receive up to 6 telephone counseling calls.
• Experimental: Varenicline + Smartphone Intervention without adherence (VAR + COMBO-B)
  Participants will receive 13 weeks of varenicline (1 titration week + 12 weeks at full twice daily 1 mg dosing) and a smartphone-based smoking cessation intervention without medication adherence components. All participants will receive up to 6 telephone counseling calls.
• Experimental: Varenicline + Lozenges + Smartphone Intervention without adherence (VAR + NRT + COMBO-B)
  Participants will receive 13 weeks of varenicline (1 titration week + 12 weeks at full twice daily 1 mg dosing), 12 weeks of nicotine lozenges (2 mg or 4 mg), and a smartphone-based smoking cessation intervention without medication adherence components. All participants will receive up to 6 telephone counseling calls.

Primary Outcome Measure

Smoking Abstinence (26 weeks post-quit) [ Time Frame: 26 weeks after the scheduled quit day ]

Central Contacts

• Shannon Gwin, Ph.D.
  (405) 271-8001
  [email protected]
• Sharon Glassman
  (405) 271-8001
  [email protected]

Locations (1)

Find similar trials in Oklahoma City, OK

Related Studies

• A Culturally Tailored Smartphone Application for African American Smokers
  Recruiting · University of Oklahoma · Oklahoma City, Oklahoma
• Empowering Cessation ACS South Region
  PHASE2/PHASE3 · Recruiting · University of Oklahoma · Oklahoma City, Oklahoma
• Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
  Recruiting · Weill Medical College of Cornell University · New York, New York
• Wellness Intervention for Smoking and HIV
  Recruiting · University of Arizona · Phoenix, Arizona